JDD in the Media

Topcials in Psoriasis Treatments

By January 21, 2020February 14th, 2020No Comments

Psoriasis is a chronic disease that can affect many areas of the body. The use of topical corticosteroids (TCS) is a common treatment, although long-term safety of TCS remains a concern.

A recent article in Dermatology Times cites a Journal of Drugs in Dermatology study which examines how Topical Halobetsol Propionate 0.01% lotion appears to “safely and quickly improve lower-extremity psoriatic lesions,” over typical TCS treatments.
“A post hoc analysis of data from phase 3 studies investigating the efficacy of halobetasol propionate 0.01% lotion for treating moderate-to-severe plaque psoriasis showed that the topical corticosteroid was associated with rapid improvement, and  findings should help dermatologists with treatment decisions for patients with disease involving leg lesions, said Neal Bhatia, M.D., director of clinical dermatology at Therapeutics Clinical Research, San Diego, and the lead author of the paper.”

At the conclusion of the eight-week treatment, the rate of success was significantly higher for patients randomized  to once-daily treatment with halobetasol 0.01% lotion compared with vehicle-treated controls (P<.001 for both comparisons).

View Article Now

You May Also Like

Atopic DermatitisDermatology RoundupJDD HighlightsJDD in the MediaThe Latest
October 17, 2024

Dermatology Roundup: Semaglutide for HS, Acne Laser Receives FDA Clearance

By Allison Sit Semaglutide – a glucagon-like peptide (GLP)-1RA – improved outcomes for obese patients with hidradenitis suppurativa (HS), according to a study presented at EADV Congress 2024. The study…
Atopic DermatitisDermatology RoundupJDD HighlightsJDD in the MediaThe Latest
September 24, 2024

Dermatology Roundup: National Eczema Association Aims to Define “Flare”

By Allison Sit A National Eczema Association (NEA) study published in JAMA Dermatology identified patient-reported attributes associated with a “flare” of atopic dermatitis. The study sought to develop a clearer…
AcneAtopic DermatitisFeatured ArticlesJDD HighlightsJDD in the MediaPsoriasisSkin of ColorThe Latest
September 19, 2024

JDD in the News: Benefits of Long-Term Ixekizumab in Psoriasis; Secukinumab in Psoriasis Patients with Skin of Color

by Allison Sit Healio wrote about two JDD studies on psoriasis treatments including one on the benefits of long-term ixekizumab. The study, “Benefits Over Five Years of Ixekizumab Treatment in…

Leave a Reply